latest news releases from the newsroom
SmallCap Sentinel: A Chorus of Nuclear Optimism
IRVINE, Calif., Dec. 19, 2007 (PRIME NEWSWIRE) -- "Despite the roller coaster in the 2007 uranium spot price that saw the resource rise from $72 at the beginning of the year to a zenith of $136 and a recent sell-off leading to yesterday's price of $90, preeminent minds in the space have glittering expectations for uranium prices," stated SmallCap Sentinel analyst D.R. Clark. "And these optimistic forecasts aren't coming from random voices, they're issued by a top CEO and a respected independent research firm."
Infinity Pharmaceuticals, Inc.
Infinity and MedImmune Initiate Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor's Potential Anti-Tumor Activity in Patients With Advanced Non-Small Cell Lung Cancer
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Dec. 19, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. today announced that the companies have initiated the Phase 2 portion of a Phase 1/2 clinical trial of IPI-504, their lead heat shock protein 90 (Hsp90) inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Enrollment has commenced at the Mount Sinai Comprehensive Cancer Center in Miami, Fla. and Yale Cancer Center in New Haven, Conn. and the study is expected to expand to additional sites throughout North America.